Trimeris, Inc. (TRMS)

Trimeris, Inc. (TRMS - Analyst Report) develops therapeutic agents for the treatment of viral diseases based on its fusion inhibition technology that blocks viral entry into host cells.

Sales of its lead drug Fuzeon have been declining dramatically since 1Q08 due to fierce competition from Selzentry and Isentress. The collaboration amendment with Roche and several management changes further cast a shadow on the company's future.

We maintain our Sell rating on Trimeris with a $0.50 price target.